论文部分内容阅读
本文应用抗-HGV酶联免疫法(EIA)和逆转录套式聚合酶链反应法(RT-PCR)检测150份乙型、120份丙型、15份戊型和49份非甲-戊型肝炎患者血清。结果显示:乙肝、丙肝、戊肝和非甲-戊型肝炎患者中抗-HGV抗体的阳性率分别为22.0％(33/150)、25.0％(30/120)、33.3％(5/15)和40.1％(20/49)。其中乙型、丙型、戊型和非甲-戊型肝炎的抗-HGV抗体阳性者中,HGV RNA的阳性率分别为58.3％(7/12)、60.0％(6/10)、40.0％(2/5)和45.5％(9/12)。说明GBV-C/HGV可与HBV、HCV或HEV合并感染,该病毒可能引起临床型肝炎。
In this study, 150 samples of B, 120 samples of C, 15 samples of E and 49 samples of non-A-PE were detected by anti-HGV enzyme-linked immunosorbent assay (EIA) and reverse transcription polymerase chain reaction Hepatitis patient serum. The results showed that the positive rates of anti-HGV antibodies in patients with hepatitis B, C, E and non-E hepatitis were 22.0% (33/150), 25.0% (30/120), 33.3% (5/15) And 40.1% (20/49). The positive rates of HGV RNA were 58.3% (7/12), 60.0% (6/10) and 40.0% in anti-HGV antibody positive patients of type B, C, (2/5) and 45.5% (9/12). This indicates that GBV-C / HGV can be co-infected with HBV, HCV or HEV, and the virus may cause clinical hepatitis.